reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
== Epidemiology == McLeod syndrome is present in 0.5 to 1 per 100,000 of the population. McLeod males have variable acanthocytosis due to a defect in the inner leaflet bilayer of the red blood cell, as well as mild hemolysis. McLeod females have only occasional acanthocytes and very mild hemolysis; the lesser severity is thought to be due to X chromosome inactivation via the Lyon effect. Some individuals with McLeod phenotype develop myopathy, neuropathy, or psychiatric symptoms, producing a syndrome that may mimic chorea.
=== Infectious diseases === Imaging infections with molecular imaging technologies can improve diagnosis and treatment follow-up. Clinically, PET has been widely used to image bacterial infections using FDG to identify the infection-associated inflammatory response. Three different PET contrast agents have been developed to image bacterial infections in vivo are [18F]maltose, [18F]maltohexaose, and [18F]2-fluorodeoxysorbitol (FDS). FDS has the added benefit of being able to target only Enterobacteriaceae.
Lymphedema is the swelling caused by the accumulation of lymph, which may occur if the lymphatic system is damaged or has malformations. It usually affects limbs, though the face, neck, and abdomen may also be affected. In an extreme state, called elephantiasis, the edema progresses to the extent that the skin becomes thick with an appearance similar to the skin on elephant limbs. Causes are unknown in most cases, but sometimes there is a previous history of severe infection, usually caused by a parasitic disease, such as lymphatic filariasis. Lymphangiomatosis is a disease involving multiple cysts or lesions formed from lymphatic vessels. Lymphedema can also occur after surgical removal of lymph nodes in the armpit (causing the arm to swell due to poor lymphatic drainage) or groin (causing swelling of the leg). Conventional treatment is by manual lymphatic drainage and compression garments. Two drugs for the treatment of lymphedema are in clinical trials: Lymfactin and Ubenimex/Bestatin. There is no evidence to suggest that the effects of manual lymphatic drainage are permanent.
Family members, including parents of adults with BPD, may find themselves in a cycle of being overly involved in the individual's life at times and, at other times, significantly detached, contributing to a sense of alienation within the family unit. Anthropologist Rebecca Lester argues that BPD is a disorder of relationships and communication, namely that a person with BPD lacks the communication skills and knowledge to interact effectively with others within their society and culture given their life experience. Personality disorders, including BPD, are associated with an increased incidence of chronic stress and conflict, reduced satisfaction in romantic partnerships, domestic abuse, and unintended pregnancies. Research indicates variability in relationship patterns among individuals with BPD. A portion of these individuals may transition rapidly between relationships, a pattern metaphorically described as "butterfly-like", characterized by fleeting and transient interactions and "fluttering" in and out of relationships. Conversely, a subgroup, referred to as "attached", tends to establish fewer but more intense and dependent relationships. These connections often form rapidly, evolving into deeply intertwined and tumultuous bonds. In certain cases, BPD may be recognized as a disability within the workplace, particularly if the condition's severity results in behaviors that undermine relationships, involve engagement in risky activities, or manifest as intense anger, thereby inhibiting the individual's ability to perform their job role effectively.
== Manufacturing == It is frequently sold as a sulfate salt known as hydroxychloroquine sulfate. In the sulfate salt form, 200 mg is equal to 155 mg of the pure form. Brand names of hydroxychloroquine include Plaquenil, Hydroquin, Axemal (in India), Dolquine, Quensyl, and Quinoric.
Sources: en.wikipedia.org
=== Organic compound peptide-based batteries === StoreDot reported in 2014 to have developed organic-compound peptide-based smartphone batteries capable of being fully charged within 30 seconds. The company said its 30-second-charging organic-compound-based battery would be commercially available for smartphones by 2016. The company announced its 5-minutes-to-full-charge organic batteries will be available for 300-mile-range electric vehicles and aerial drones by 2020. The company acknowledged in 2015 that its claims regarding its organic batteries have not been scientifically peer-reviewed.
=== Aviptadil === In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials. In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir. In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care. On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York, citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil. On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it. On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo.
The city's automotive industry played a pivotal role in the Italian economic miracle of the 1950s and 1960s, attracting hundreds of thousands of migrants to the city, particularly from the rural southern regions of Italy. The number of migrants was so high that Turin was said to be "the third southern Italian city after Naples and Palermo". The population soon reached 1 million in 1960 and peaked at almost 1.2 million in 1971. The exceptional growth gains of the city gained it the nickname of Capitale dell'automobile (Automobile Capital), being often compared with Detroit, the major centre of the U.S. automobile industry (these cities were 'twinned' as sister cities in 1998). In the 1970s and 1980s, the oil and automotive industry crisis severely hit the city, and its population began to sharply decline as jobs were lost. In 30 years, the population decreased by more than one-fourth of the 1971 total. The long population decline of the city has begun to reverse itself only in recent years; the population grew from 865,000 to slightly over 900,000 by the end of the 20th century. In 2006, Turin hosted the Winter Olympic Games.
Russia launched around 76 missiles on Kyiv, Kharkiv, Poltava, and Kremenchuk, destroying infrastructure. Reports suggested at least four were killed in Kryvyi Rih. The missiles were fired at nine power plants; Ukraine claimed 60 were intercepted. A Ukrainian strike on the village of Lantrativka, in Luhansk Oblast, officially killed 11 Russian trench diggers, but eyewitnesses claimed 84 were killed.
Sources: en.wikipedia.org
Concerns expressed by some politicians on the subject of salvia reflect those of the media, with comparisons to LSD and particular focus on "protecting our children" being echoed; and with legislative proposals following soon after news stories breaking. Some arguments against salvia have been of a preventative nature, "We need to stop this before it gets to be a huge problem not after it gets to be a huge problem," or of an imitative nature, "The Australians have clearly found a problem with it. There's obviously a risk in people taking it." Concerns about driving while under the influence of salvia have also been expressed. Opponents of more prohibitive measures against salvia argue that such reactions are largely due to an inherent prejudice and a particular cultural bias rather than any actual balance of evidence, pointing out inconsistencies in attitudes toward other more toxic and addictive drugs such as alcohol and nicotine. While not objecting to some form of legal control, in particular with regard to the sale to minors or sale of enhanced high-strength extracts, most salvia proponents otherwise argue against stricter legislation. Those advocating consideration of Salvia divinorum's potential for beneficial use in a modern context argue that more could be learned from Mazatec culture, where salvia is not really associated with notions of drug taking at all and it is rather considered as a spiritual sacrament. In light of this it is argued that Salvia divinorum could be better understood more positively as an entheogen rather than pejoratively as a hallucinogen.
consistent, clinically established pharmacodynamic relationships between plasma drug concentrations and pharmacological efficacy and/or toxicity; significant between-patient pharmacokinetic variability, making a standard dosage achieve different concentration levels among patients (while the drug disposition remains relatively stable in a given patient); narrow therapeutic window of the drug, which forbids giving high doses in all patients to ensure overall efficacy; drug dosage optimization not achievable based on clinical observation alone; duration of the treatment and criticality for patient's condition justifying dosage adjustment efforts; potential patient compliance problems that might be remedied through concentration monitoring. TDM determinations are also used to detect and diagnose poisoning with drugs, should the suspicion arise. Examples of drugs widely analysed for therapeutic drug monitoring:
Avoiding smoking Cutting down on fats to help reduce the amount of plaque buildup Eating a healthy diet, including plenty of fruits and vegetables Limiting sodium in the diet, thereby reducing blood pressure Exercising regularly Moderating intake of alcohol, stimulants, sympathomimetics, etc. Maintaining a healthy weight In addition, it is important to control any underlying medical conditions that may increase the risk of stroke or TIA, including:
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.